An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
It is recognized that the measurable disease RECIST criteria response rate with mTOR
inhibition is likely to be low and that the benefit of such therapy will also include
effects on disease stabilization. Disease stabilization is difficult to interpret in the
phase II setting. Thus, it is desirable to develop biomarkers which will provide additional
information on novel treatment effects and how they might relate to disease progression
Observational
Time Perspective: Prospective
This is an exploratory study. Correlations between biomarkers and baseline factors and treatment outcomes will be made
Christian Kollmannsberger, MD
Principal Investigator
BC Cancer Agency- Vancouver
Canada: Health Canada
KNC-001
NCT00538772
July 2008
Name | Location |
---|